KSI 301 for Wet AMD
Age-related macular degeneration (AMD) is a degenerative disease of the retina. Wet AMD is caused when abnormal blood vessels (choroidal neovascularization) grow underneath the retina. Choroidal neovascularization leads to fluid and blood under the retina causing visual distortion and acute vision loss. If untreated or undertreated, wet AMD leads to hemorrhage, scar formation, and permanent damage that results in blindness.
KSI 301 is a novel anti-VEGF biologic in development with an extended ocular half-life. It offers the potential for patients to remain on mechanism for a longer interval between consecutive intravitreal injections. It aims to improve real world outcomes of anti-VEGF therapy which are currently restricted by treatment burden and insufficient durability of existing anti-VEGF agents.
KSI 301 for Diabetic Retinopathy
Diabetes is the leading cause of blindness among working-age adults. Diabetic retinopathy (DR) is caused by elevated blood sugar levels over time. In its early stages, blood vessels in the retina are damaged and leak fluid. In advanced stages, new and abnormal blood vessels form which may break and bleed. Fluid and hemorrhage interfere with vision and may further cause irreversible visual impairment due to retinal scarring and retinal detachment.
KSI 301 is a novel biologic in development that may block the ocular effects of high blood sugar levels, potentially preventing or slowing the progression of diabetic eye disease.
KSI 501 for Wet AMD and Diabetic Retinopathy
KSI-501 is a novel dual inhibitor biologic in development that blocks activation of both VEGF and IL-6 and may be suitable as a next generation therapy for the treatment and prevention of neovascular retinal diseases such as wet AMD and DR.
A Breakthrough Platform
Our medicines are built on a high science Antibody Biopolymer Conjugate, or ABC™, product platform which is designed to maintain potent and effective drug levels in ocular tissue.